Meng Weizhe, Li Ronghua, Xie Xiufen
Weizhe Meng, Binzhou People's Hospital, Shandong, 256610, China.
Ronghua Li, Binzhou People's Hospital, Shandong, 256610, China.
Pak J Med Sci. 2019 Nov-Dec;35(6):1493-1498. doi: 10.12669/pjms.35.6.512.
To explore the clinical efficacy of intravitreal injection of conbercept in combination with retinal laser photocoagulation in the treatment of diabetic macular edema.
Ninety patients with diabetic macular edema were selected and grouped into an observation group and a control group using random number table, 45 patients (45 eyes) each group. The control group was given retinal laser photocoagulation, while the observation group was given intravitreal injection of Conbercept on the basis of panretinal photocoagulation. The Best Corrected Visual Acuity (BCVA), thickness of retinal nerve fibre layer (RNFL) and macular thickness were measured through relevant examinations before and after treatment. The intraocular pressures of patients in the two groups were evaluated, and moreover the complications were recorded.
The RNFL thickness and macular thickness of the two groups had no statistically significant differences before treatment (P>0.05) and decreased significantly after treatment; the decrease amplitude of the observation group was significantly larger than that of the control group (P<0.05). The BCVA of both groups significantly increased in the 1, 2 and 4 week after treatment (P<0.05); the increase amplitude of BCVA of the observation group was more significant than that of the control group at different time points after treatment (P<0.05). The intraocular pressure of the observation group was not significantly different with that of the control group in the 1, 2 and 4 week after treatment (P>0.05). There were no severe eye complications and systemic adverse reactions in both groups in the process of follow up.
Intravitreal injection of conbercept in combination with retinal laser photocoagulation performs better in improving the BCVA and central macular thickness of patients with diabetic macular edema compared to retinal laser photocoagulation and has high safety.
探讨玻璃体腔注射康柏西普联合视网膜激光光凝治疗糖尿病性黄斑水肿的临床疗效。
选取90例糖尿病性黄斑水肿患者，采用随机数字表法分为观察组和对照组，每组45例（45眼）。对照组给予视网膜激光光凝治疗，观察组在全视网膜光凝的基础上给予玻璃体腔注射康柏西普。治疗前后通过相关检查测量最佳矫正视力（BCVA）、视网膜神经纤维层（RNFL）厚度及黄斑厚度。评估两组患者的眼压，并记录并发症。
两组治疗前RNFL厚度和黄斑厚度比较，差异无统计学意义（P>0.05），治疗后均显著降低；观察组降低幅度明显大于对照组（P<0.05）。两组治疗后1、2、4周BCVA均显著提高（P<0.05）；治疗后不同时间点观察组BCVA提高幅度均明显大于对照组（P<0.05）。治疗后1、2、4周观察组眼压与对照组比较，差异无统计学意义（P>0.05）。随访过程中两组均未出现严重眼部并发症及全身不良反应。
玻璃体腔注射康柏西普联合视网膜激光光凝治疗糖尿病性黄斑水肿在改善患者BCVA及黄斑中心厚度方面较单纯视网膜激光光凝效果更好，且安全性高。
